Lilly reports orforglipron maintains weight loss in Phase 3 ATTAIN-MAINTAIN
The oral GLP-1 candidate is being positioned for long-term weight maintenance after initial reduction, according to the trial readout.
MH
By Maren Holt · Senior Reporter, GLP-1
Dec 23 03:00 ETSource: Pharmacy Times
The wire
- 01Pharmacy Times reports the Phase 3 ATTAIN-MAINTAIN trial found orforglipron supported weight maintenance in participants with obesity or overweight.
- 02An oral small-molecule GLP-1 that does not require injection or refrigeration would change dispensing, storage and adherence conversations for pharmacists and telehealth prescribers.
- 03Detailed endpoint figures, dosing arms and safety data were not included in the report; full results and regulatory review remain the gating items.
From the source
Read at pharmacytimes.comOrforglipron Shows Strong Weight Maintenance in Phase 3 ATTAIN-MAINTAIN Trial